RecruitingAdvanced/Metastatic Solid TumorsColorectal CancerGastric Cancer

A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors

Eligible age

18+ yrs

Accepts

All genders

Locations

16 states

Healthy volunteers

See if you qualify for this study

Answer a few quick questions about your location and health. Takes about a minute.

Check my eligibility →

About this study

This is a Phase 1/2 open-label, multi-center, multi-national study with an initial dose escalation part to determine the recommended Phase II dose (RP2D) of MCLA-158 single agent in patients with mCRC. The dose escalation part has been completed and the RP2D will be further evaluated in an expansion part of the study. Cohorts of selected solid tumor indications for which there is evidence of EGFR dependency and potential sensitivity to EGFR inhibition will be evaluated including head and neck cancer and metastatic colorectal cancer (mCRC). The study will further assess the safety, tolerability, PK, PD, immunogenicity, and anti-tumor activity of MCLA-158 in monotherapy or in combination with other therapies.

Sponsor: Merus B.V.

You may qualify if…

✓ Histologically or cytologically confirmed solid tumors with evidence of metastatic or locally advanced disease not amenable to standard therapy with curative intent.
✓ A baseline fresh tumor sample (FFPE) from a metastatic or primary site (if safe/feasible).
✓ Amenable for biopsy (if safe/feasible).
✓ Measurable disease as defined by RECIST version 1.1 by radiologic methods.
✓ Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
✓ Life expectancy ≥ 12 weeks, as per investigator.
✓ Left ventricular ejection fraction (LVEF) ≥ 50% by echocardiogram (ECHO) or multiple gated acquisition scan (MUGA).
✓ Adequate organ function

You may not qualify if…

✕ Central nervous system metastases that are untreated or symptomatic, or require radiation, surgery, or continued steroid therapy to control symptoms within 14 days of study entry.
✕ Known leptomeningeal involvement.
✕ Participation in another clinical study or treatment with any investigational drug within 4 weeks prior to study entry.
✕ Any systemic anticancer therapy within 4 weeks or 5 half-lives whichever is shorter of the first dose of study treatment. For cytotoxic agents that have major delayed toxicity ( e.g. mitomycin C,nitrosoureas), or anticancer immunotherapies, a washout period of 6 weeks is required.
✕ Requirement for immunosuppressive medication (e.g. methotrexate, cyclophosphamide)
✕ Major surgery or radiotherapy within 3 weeks of the first dose of study treatment. Patients who received prior radiotherapy to ≥25% of bone marrow are not eligible, irrespective of when it was received.
✕ Persistent grade \>1 clinically significant toxicities related to prior antineoplastic therapies (except for alopecia); stable sensory neuropathy ≤ grade 2 NCI-CTCAE v4.03 is allowed.
✕ History of hypersensitivity reaction to any of the excipients of petosemtamab, human proteins or any non-IMP treatment required for this study.